Hindbrain leptin receptor stimulation enhances the anorexic response to cholecystokinin.
Leptin is thought to reduce food intake, in part, by increasing sensitivity to satiation signals, including CCK. Leptin action in both forebrain and hindbrain reduces food intake, and forebrain leptin action augments both the anorexic and neuronal activation responses to CCK. Here, we asked whether leptin signaling in hindbrain also enhances these responses to CCK. We found that food intake was strongly inhibited at 30 min after a combination of 4th-intracerebroventricular (4th-icv) leptin injection and intraperitoneal CCK administration, whereas neither hormone affected intake during this period when given alone. Leptin injections targeted directly at the dorsal vagal complex (DVC) similarly enhanced the anorexic response to intraperitoneal CCK. Intra-DVC leptin injection also robustly increased the number of neurons positive for phospho-STAT3 staining in the area surrounding the site of injection, confirming local leptin receptor activation. Conversely, the anorexic response to 4th-icv leptin was completely blocked by IP devazepide, a CCKA-R antagonist, suggesting that hindbrain leptin reduces intake via a mechanism requiring endogenous CCK signaling. We then asked whether hindbrain leptin treatment enhances the dorsomedial hindbrain, hypothalamus, or amygdala c-Fos responses to IP CCK. We found that, in contrast to the effects of forebrain leptin administration, 4th-icv leptin injection had no effect on CCK-induced c-Fos in any structures examined. We conclude that leptin signaling in either forebrain or hindbrain areas can enhance the response to satiation signals and that multiple distinct neural circuits likely contribute to this interaction.
Williams
Diana L
DL
Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, Florida 32306, USA. williams@psy.fsu.edu
Baskin
Denis G
DG
Schwartz
Michael W
MW
D000818:Animals; D000855:Anorexia / Q000139:chemically induced* / Q000378:metabolism*; D002766:Cholecystokinin / Q000008:administration & dosage / Q000502:physiology*; D020109:Devazepide / Q000494:pharmacology; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects / Q000502:physiology; D006727:Hormone Antagonists / Q000494:pharmacology; D007276:Injections, Intraventricular; D020738:Leptin / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D054411:Receptors, Leptin / Q000187:drug effects / Q000378:metabolism*; D012249:Rhombencephalon / Q000378:metabolism*; D050796:STAT3 Transcription Factor / Q000378:metabolism; D012528:Satiety Response / Q000187:drug effects / Q000502:physiology; D014630:Vagus Nerve / Q000187:drug effects / Q000502:physiology
D006727:Hormone Antagonists; D020738:Leptin; D016760:Proto-Oncogene Proteins c-fos; D054411:Receptors, Leptin; D050796:STAT3 Transcription Factor; C494088:Stat3 protein, rat; D002766:Cholecystokinin; D020109:Devazepide